Key facts
- Global drugmakers are investing billions in U.S. operations.
- Investments aim to expand manufacturing and research capabilities.
- Investments seek to mitigate supply chain risks.
- Drugmakers aim to secure exemptions from potential 100% tariffs on branded drugs.
- President Trump threatened 100% tariffs on French wines and champagne.
- Tariffs are a response to France's digital tax on U.S. tech giants.
- French President Emmanuel Macron stated France will not yield to pressure.
Global drugmakers are making substantial investments in their U.S. operations, pledging billions of dollars to expand manufacturing and research capabilities. These strategic investments are aimed at strengthening the companies' infrastructure within the United States and mitigating risks associated with global supply chains. A significant factor driving these investments is the potential for exemptions from proposed 100% tariffs on branded drugs, which have been threatened by President Trump.
In a separate but related development, President Trump has also threatened to impose 100% tariffs on French wines and champagne. This action is a direct response to France's implementation of a digital tax that targets U.S. tech giants. French President Emmanuel Macron has publicly stated that France will not succumb to this pressure and will not scrap its digital tax.